Redosable Gene-Therapy Developer Generation Bio Wins $100M Series B Financing

Generation Bio, a developer of redosable gene therapies, said today it has closed on a $100 million Series B financing, with proceeds intended to advance its first two treatment candidates through Investigational New Drug (IND)-enabling studies, and develop additional programs targeting genetic diseases of the retina, central nervous system (CNS), and lungs.Generation Bio’s treatments are based on its proprietary GeneWave™ technology, designed to create a new class of genetic medicin